Avilamycin

1404.243

1334.437378

Colorless, needle-shaped crystals from acetone-ether

385

11.81

1.5±0.1 g/cm3

188-189℃

1.615

Store at less than or equal to 25 °C (77 °F). Excursions to 40 °C (104 °F) are acceptable. Avoid excessive moisture.

D20 +0.8° (c = 1.165 in abs ethanol) and -7.7° (c = 1.083 in chloroform)

Oligosaccharide antibiotics are sensitive to acid pH because of the ortho-ester linkages. Acidic phenolic group makes them relatively unstable to handling conditions.

Dihydrate; colorless fine plates from acetone/ether; MP: 188-189 °C. Specific optical rotation at 20 °C/D: -4.8 deg (C = 1.44 in chloroform). UV Max (methanol): 228, 284 nm (log epsilon 4.12, 3.33) /Avilamycin C/|Reactive groups are the glycosidic linkages, the hydroxyl groups, the carbonyl groups, and the phenolic groups.

P264, P280, P305+P351+P338, P33, P313

H319

SRP: Expired or waste pharmaceuticals shall carefully take into consideration applicable DEA, EPA, and FDA regulations. It is not appropriate to dispose by flushing the pharmaceutical down the toilet or discarding to trash. If possible return the pharmaceutical to the manufacturer for proper disposal being careful to properly label and securely package the material. Alternatively, the waste pharmaceutical shall be labeled, securely packaged and transported by a state licensed medical waste contractor to dispose by burial in a licensed hazardous or toxic waste landfill or incinerator.

|Warning|H319 (100%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]|P264, P280, P305+P351+P338, and P337+P313|Aggregated GHS information provided by 37 companies from 2 notifications to the ECHA C&L Inventory.

Operators mixing and handling Kavault should use protective clothing, impervious gloves, goggles, and an approved dust mask.

Wash hands thoroughly with soap and water after handling.|SRP: The scientific literature for the use of contact lenses by industrial workers is inconsistent. The benefits or detrimental effects of wearing contact lenses depend not only upon the substance, but also on factors including the form of the substance, characteristics and duration of the exposure, the uses of other eye protection equipment, and the hygiene of the lenses. However, there may be individual substances whose irritating or corrosive properties are such that the wearing of contact lenses would be harmful to the eye. In those specific cases, contact lenses should not be worn. In any event, the usual eye protection equipment should be worn even when contact lenses are in place.

Avilamycin may be irritating to the eyes ... .

IDENTIFICATION AND USE: Avilamycin is an antibiotic mainly active against Gram-positive bacteria, including Bacillus spp., Clostridium spp., Corynebacterium bovis, Enterococcus spp., Lactobacillus spp., Listeria monocytogenes, Micrococcus luteus, Staphylococcus aureus and Streptococcus spp. Avilamycin is intended for use as a veterinary medicine in chickens, turkeys, pigs and rabbits to control bacterial enteric infections. HUMAN EXPOSURE AND TOXICITY: Avilamycin may be irritating to the eyes and may cause allergic reactions in those hypersensitive to avilamycin. ANIMAL STUDIES: The acute toxicity of avilamycin has been evaluated using various routes of administration in mice, rats and rabbits. The acute intraperitoneal toxicity of avilamycin was more severe than its oral or dermal toxicity. However, the deaths observed after intraperitoneal administration were mainly due to the inflammatory reactions to the unabsorbed avilamycin in the abdominal cavity rather than to the toxicity of avilamycin itself. Mice were fed avilamycin incorporated into the pelleted diet at levels of 0, 30, 300 or 3000 mg avilamycin activity/kg diet continuously for 28 days. There was a slight increase in feed intake and body weight of the males given 450 mg avilamycin activity/kg bw per day. In another study, rats received dietary doses of 0, 4, 6 or 10% dried fermentation product of avilamycin (14.9% avilamycin activity) for 2 weeks. The only treatment-associated finding was brown to black discoloration of the waste trays by urine, although urine was yellow in the bladder or when freshly voided. Avilamycin (mycelial cake form, activity 7.83%) was fed to pigs at levels of 0, 30, 300 and 3000 mg avilamycin activity/kg in the diet for 21 weeks, followed by a 4-week withdrawal period. Some blood biochemistry parameters, such as gamma glutamyl transferase (GGT), aspartate aminotransferase (AST), sodium and inorganic phosphorus, were changed from control values, but those changes were weak and in the normal range In a 2-year experiment, male and female rat litters were fed avilamycin (derived from mycelial cake of 7% activity) at doses of 0, 30, 300 or 3000 mg avilamycin activity/kg in the diet and pure avilamycin at 3000 mg avilamycin activity/kg in the diet during the whole period of the study. The litters were from parent rats fed avilamycin at the same doses of 0, 30, 300 or 3000 mg avilamycin activity/kg in the diet for 1 week and then mated and maintained on their treatments during gestation and lactation. The mortality was 58-78%, with no difference between treatments. Clotting times were significantly decreased, with dose dependency in males at 15 and 150 mg avilamycin activity/kg bw per day, where avilamycin was derived from mycelial cake, on weeks 13, 26, 52 and 78. However, they recovered at the last two sampling times (weeks 104 and 112). There was a non-statistically significant increase in pancreatic exocrine adenomas in male rats that were fed avilamycin derived from mycelial cake at 15 and 150 mg avilamycin activity/kg bw per day. A higher incidence of thyroid parafollicular cell carcinoma was also observed in male rats treated with avilamycin derived from mycelial cake at 15 and 150 mg avilamycin activity/kg bw per day, without statistical significance. No thyroid parafollicular cell carcinoma was found at 1.5 mg avilamycin activity/kg bw per day for the mycelial cake and 150 mg avilamycin activity/kg bw per day for the pure form of avilamycin. Pregnant rabbits were administered a dried fermentation product of avilamycin (17.8% activity) by oral gavage in daily doses of 0, 250, 716 and 2000 mg/kg bw. Abortions occurred in two rabbits from the low dose group and one rabbit from both middle and high dose groups. All except one of these rabbits had diarrhea or were anorectic prior to abortion. The low incidence of abortions that occurred in all treatment groups was regarded as a secondary consequence of maternal toxicity. Avilamycin was not mutagenic in the reverse mutation assay with Salmonella typhimurium strains TA98, TA100, TA1535, TA1537, TA1538, G46, C3076 and D3052 and Escherichia coli strains WP2 and WP2uvrA both with and without S9 activation. Also, avilamycin did not present any genotoxicity in a deoxyribonucleic acid (DNA) repair assay using primary cultures of adult rat hepatocytes, in a forward mutation assay using L5178Y mouse lymphoma cells and in a chromosomal aberration assay using Chinese hamster ovary cells both with and without S9 activation. Avilamycin was not mutagenic in sister chromatid exchange assays in bone marrow of Chinese hamsters that were orally administered avilamycin and in micronucleus tests with bone marrow of mice treated with avilamycin..

LD50 Mouse (female) ip 1798.9 mg/kg bw|LD50 Mouse (male) ip 3435.1 mg/kg bw|LD50 Rat (female) ip 3114.5 mg/kg bw|LD50 Rat (male) ip 2319.3 mg/kg bw|For more Non-Human Toxicity Values (Complete) data for AVILAMYCIN (6 total), please visit the HSDB record page.

Polyether antibiotic complex produced by Streptomyces viridochromogenes

Avilamycin's production and use as an antibiotic(1) may result in its release to the environment through various waste streams(SRC).

TERRESTRIAL FATE: Based on a classification scheme(1), an estimated Koc value of >1X10+5(SRC), determined from a structure estimation method(2), indicates that avilamycin is expected to be immobile in soil(SRC). Volatilization of avilamycin from moist soil surfaces is not expected to be an important fate process(SRC) given an estimated Henry's Law constant of <1X10-10 atm-cu m/mole(SRC), using a fragment constant estimation method(2). Avilamycin is not expected to volatilize from dry soil surfaces(SRC) based upon an estimated vapor pressure of <1X10-10 mm Hg at 25 °C(SRC), determined from a fragment constant method(2). Biodegradation data in soil were not available(SRC, 2015).|AQUATIC FATE: Based on a classification scheme(1), an estimated Koc value of >1X10+5(SRC), determined from a structure estimation method(2), indicates that avilamycin is expected to adsorb to suspended solids and sediment(SRC). Volatilization from water surfaces is not expected(3) based upon an estimated Henry's Law constant of <1X10-10 atm-cu m/mole(SRC), developed using a fragment constant estimation method(2). Estimated hydrolysis half-lives were 5.6 years and 200 days at pH 7 and 8, respectively(2). According to a classification scheme(4), an estimated BCF of 20(SRC), from an estimated log Kow of 2.49(2) and a regression-derived equation(2), suggests the potential for bioconcentration in aquatic organisms is low(SRC). Biodegradation data in water were not available(SRC, 2015).|ATMOSPHERIC FATE: According to a model of gas/particle partitioning of semivolatile organic compounds in the atmosphere(1), avilamycin, which has an estimated vapor pressure of <1X10-10 mm Hg at 25 °C(SRC), determined from a fragment constant method(2), is expected to exist solely in the particulate phase in the ambient atmosphere. Particulate-phase avilamycin may be removed from the air by wet and dry deposition(SRC). Avilamycin contains chromophores that absorb at wavelengths >290 nm(3) and, therefore, may be susceptible to direct photolysis by sunlight(SRC).

A base-catalyzed second-order hydrolysis rate constant of 0.039 L/mole-sec(SRC) was estimated for avilamycin using a structure estimation method(1); this corresponds to half-lives of 5.6 years and 200 days at pH values of 7 and 8, respectively(1). Avilamycin contains chromophores that absorb at wavelengths >290 nm(2) and, therefore, may be susceptible to direct photolysis by sunlight(SRC).

An estimated BCF of 20 was calculated in fish for avilamycin(SRC), using an estimated log Kow of 2.49(1) and a regression-derived equation(1). According to a classification scheme(2), this BCF suggests the potential for bioconcentration in aquatic organisms is low(SRC).

Using a structure estimation method based on molecular connectivity indices(1), the Koc of avilamycin can be estimated to be >1X10+5(SRC). According to a classification scheme(2), this estimated Koc value suggests that avilamycin is expected to be immobile in soil.

The Henry's Law constant for avilamycin is estimated as <1X10-10 atm-cu m/mole(SRC) using a fragment constant estimation method(1). This Henry's Law constant indicates that avilamycin is expected to be essentially nonvolatile from water and moist soil surfaces(2). Avilamycin is not expected to volatilize from dry soil surfaces(SRC) based upon an estimated vapor pressure of <1X10-10 mm Hg(SRC), determined from a fragment constant method(1).

Occupational exposure to avilamycin may occur through inhalation and dermal contact with this compound at workplaces where avilamycin is produced or used. (SRC)

Anti-Bacterial Agents|MEDICATION (VET): Avilamycin is mainly active against Gram-positive bacteria, including Bacillus spp., Clostridium spp., Corynebacterium bovis, Enterococcus spp., Lactobacillus spp., Listeria monocytogenes, Micrococcus luteus, Staphylococcus aureus and Streptococcus spp. Avilamycin is intended for use as a veterinary medicine in chickens, turkeys, pigs and rabbits to control bacterial enteric infections.|MEDICATION (VET): For the reduction in incidence and overall severity of diarrhea in the presence of pathogenic Escherichia coli in groups of weaned pigs. /Included in US product label/

Avilamycin has not been demonstrated to be effective in pigs showing clinical signs of diarrhea prior to the start of medication. The safety of avilamycin has not been established in swine intended for breeding purposes.|To assure responsible antimicrobial drug use in pigs, do not administer to pigs 14 weeks of age or older. Do not administer medicated feed containing avilamycin to pigs for more than a lifetime total of 42 days.

Enterococci were isolated from fecal droppings of chickens in broiler and layer farms and the susceptibilities to nine therapeutic antimicrobial agents and six growth-promoting antibiotics were determined by the agar dilution method. ... Resistance to growth-promoting antibiotics such as avilamycin, salinomycin and virginiamycin was common among isolates from broiler farms. Of the E. faecium isolates from broiler farms, 12.4% were resistant to avilamycin ... .|This study describes the changes in the occurrence of resistance to avilamycin among Enterococcus faecium from broilers in Denmark and the epidemiological association between usage of avilamycin for growth promotion and the occurrence of avilamycin-resistant E. faecium on broiler farms. The consumption of avilamycin for growth promotion increased from 10 kg in 1990 to 2,740 kg 1996 and decreased in the following years to only 7 kg in 1998. Most of this has been used for broilers. As part of the nationwide monitoring program for antimicrobial resistance, a total of 473 E. faecium isolates from broilers and 290 isolates from pigs have been tested for their susceptibility to avilamycin from 1995 to 1998. A very limited number of isolates from pigs were resistant to avilamycin, whereas the occurrence of resistance among isolates from broilers increased from 63.6% at the end of 1995 to a maximum of 80.7% during the last half of 1996. Since then, the occurrence of resistance has decreased to 23.3% in the last half of 1998. The epidemiological association between consumption of avilamycin and occurrence of resistant E. faecium fecal droppings were examined on 10 poultry farms that had not used avilamycin for growth promotion during 1996 or 1997 and eight farms that had used avilamycin during 1997. We tested a total of E. faecium isolates from the exposed farms and 104 from the nonexposed farms for their susceptibility to avilamycin. Resistant isolates were found on all eight exposed farms, and on seven of 10 nonexposed farms. Sixty-four isolates (72%) from the exposed farms were resistant, compared with 24 (23%) of the isolates from nonexposed farms. The adjusted chi-square p value equaled 0.01065, and showed a significant association between use of avilamycin and occurrence of resistance. The national monitoring program showed a decrease in the occurrence of resistance following a decreased use of avilamycin in Denmark, and the epidemiological study showed a statistically significant association between the use of avilamycin for growth promotion and the occurrence of avilamycin-resistant E. faecium on broiler farms.

Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)

(14)C-Avilamycin was fed to growing swine at a level of 60-80 ppm (1.5-2 times the recommended use level), and tissues were assayed for radioactivity (RA). At a practical zero withdrawal swine fed 60 ppm of uniformly labeled (U-14)C-avilamycin for 14 days had RA residues of 0.14, 0.66, 0.34, and 0.55 ppm in muscle, liver, kidney, and fat, respectively. Swine fed 80 ppm of (14)C-avilamycin labeled in the dichloroisoeverninic acid portion had residues 3-5 times lower, indicative that most of the residue was derived from the oligosaccharide portion of avilamycin. The primary metabolite in liver and feces was flambic acid. Most of the RA in fat from swine fed (U-14)C-avilamycin was in the fatty acids. (14)C-Avilamycin was excreted rapidly and nearly quantitatively by swine, with 5% of the dose in the murine and the remainder in feces. The excretion pattern and metabolic profile of (14)C-avilamycin in the rat were similar to swine.|Seven female and four to five male starter pigs weighing 7-12 kg were fed standard diets containing 20 mg avilamycin/kg in three different product forms (crystalline, micronized and non-micronized) for 6 days. The feces collected from pigs that were fed crystalline, micronized and non-micronized product had microbiologically active residues that represented 2.0%, 4.5% and 15.0%, respectively, of the residues of avilamycin and its degradation products, as determined by gas chromatographic assays. The faeces contained an average of 0.94, 2.28 and 8.45 ug of microbiologically active residues per gram for pigs fed crystalline, micronized and non-micronized avilamycin, respectively. The gas chromatographic assay, which determined the total residues of avilamycin plus any degradation products that hydrolyse to DIA, indicated that the faeces contained 43.3, 40.1 and 43.4 ug/g for pigs fed the crystalline, micronized and non-micronized product forms, respectively.|... Two crossbred female pigs weighing approximately 40 kg each received 0.9 kg of feed containing unlabelled avilamycin at 60 mg activity/kg in the diet twice daily for 7 days. After being fed the unlabelled drug, each pig received a one-time dose of 120 mg of (14)C-avilamycin (9.3 kBq/mg) incorporated into 450 g of diet. After the consumption of the diet containing (14)C-avilamycin, the animals were given an additional 450 g of unmedicated diet. The female pigs were then fed twice daily with 0.9 kg of unmedicated feed for the duration of the experiment. Most of the (14)C residues in both pigs were excreted in the first 4 days, with over 91% eliminated on days 2 and 3. The peak excretion of (14)C residues in urine occurred in the first 24-hr collection period, with 2.75% and 3.30% recovery for the two animals. During the 9-day collection period, the two pigs excreted 96.9% and 99.0%, respectively, of the total dose administered. An average of 93.4% of the excreted dose was found in the feces, and 4.54% was found in the urine.|Six male and six female 7-week-old broiler chickens (Hubbard-White Mountain Cross) were fed a standard broiler finishing ration containing 14.16 mg (14)C-avilamycin/kg diet (equivalent to 15 mg avilamycin activity/kg in the diet) for 4, 7 or 10 days. Medicated ration was provided ad libitum throughout the dosing phase. At the end of each dosing period, two birds of each sex were deprived of food and water for 6 h, and then samples of muscle, liver, abdominal fat, kidney and skin with subcutaneous fat were collected for radiochemical analysis. Radioactive residue levels in muscle and kidney were lower than the detection limits of 0.008 and 0.024 ug/g, respectively, at all sampling times. The mean peak level of 0.039 ug/g was attained in liver after 7 days of dosing. After 10 days of dosing, the mean total radioactive residues in skin, liver and fat, expressed as avilamycin equivalents, were 0.018, 0.022 and 0.024 ug/g, respectively. Steady-state concentrations of radioactivity were attained in all tissues within 4-7 days after the initiation of dosing.|For more Absorption, Distribution and Excretion (Complete) data for AVILAMYCIN (6 total), please visit the HSDB record page.

Six rats (three males and three females) were fed a ration containing uniformly radiolabelled (14)C- avilamycin at a concentration of 550 mg/kg diet for 4.5 days. Urine and feces were collected during the dosing period, and livers were collected at zero withdrawal. Avilamycin A constituted approximately 19% of the fecal radioactivity. There were three major metabolites derived from the oligosaccharide and eurekanate portion of avilamycin in fecal samples. The most abundant metabolite in feces was flambic acid (metabolite B). Flambic acid was relatively unstable and readily converted to flambalactone (metabolite A).|The minimum inhibitory concentrations (MIC) of eight antibiotics and two anticoccidial agents were determined for Clostridium perfringens strains isolated from 26 commercial broiler farms and 22 commercial turkey farms. Isolates were obtained from the intestines of birds on the farm or as the processing plant using standard culture and identification techniques. The microbroth dilution test was used to determine the MIC for each compound. Most isolates from chickens had MICs in the range of 2-16 mg/L for tilmicosin, tylosin and virginiamycin, whereas the MICs for avilamycin, avoparcin, monensin, narasin and penicillin were < or = 1 mg/L. Most strains from chickens had high MICs (> or = 64 mg/L) and appeared to be resistant to bacitracin and lincomycin. Most turkey isolates had MICs in the range of 2-16 mg/L for bacitracin, tilmicosin, tylosin and virginiamycin, with strains exhibiting MICs < or = 1 mg/L for avilamycin, avoparcin, monensin, narasin and penicillin. Several turkey isolates had MICs > or = 64 mg/L to lincomycin. No attempt was made to associate farm usage of a particular antibiotic to the antibiograms.|... Nine crossbred pigs (five males and four females) weighing approximately 44 kg each were fed a ration containing 76.19 mg (14)C-avilamycin/kg in the diet (equivalent to 80 mg avilamycin activity/kg in the diet) at 12-hr intervals for 4, 7 or 10 days. ... One major metabolite observed in the extracts of both liver and excreta was flambic acid, which was formed as a result of cleavage of the ortho ester linking the C and D rings of avilamycin. Flambic acid represented 40-50% of the total radioactive residue in urine and feces and 15-20% of the residue in liver.|Avilamycin is poorly absorbed and is extensively metabolized in the gut of pigs. Only about 8% of total radioactivity in pig feces was attributable to parent avilamycin. Metabolites were found in liver, whereas they were not detected in other tissues. The primary metabolite is flambic acid, representing 40-50% of the total radioactive residue in urine and feces and 15-20% of the residue in liver. No microbiologically active residues were detected in liver. Avilamycin is unlikely to be persistent in the environment following excretion from treated animals, as it is highly metabolized or degraded in animals.

The antibiotic growth promoter avilamycin inhibits protein synthesis by binding to bacterial ribosomes. Here the binding site is further characterized on Escherichia coli ribosomes. The drug interacts with domain V of 23S rRNA, giving a chemical footprint at nucleotides A2482 and A2534. Selection of avilamycin-resistant Halobacterium halobium cells revealed mutations in helix 89 of 23S rRNA. Furthermore, mutations in helices 89 and 91, which have previously been shown to confer resistance to evernimicin, give cross-resistance to avilamycin. These data place the binding site of avilamycin on 23S rRNA close to the elbow of A-site tRNA. It is inferred that avilamycin interacts with the ribosomes at the ribosomal A-site interfering with initiation factor IF2 and tRNA binding in a manner similar to evernimicin.

/SRP:/ Immediate first aid: Ensure that adequate decontamination has been carried out. If patient is not breathing, start artificial respiration, preferably with a demand valve resuscitator, bag-valve-mask device, or pocket mask, as trained. Perform CPR if necessary. Immediately flush contaminated eyes with gently flowing water. Do not induce vomiting. If vomiting occurs, lean patient forward or place on the left side (head-down position, if possible) to maintain an open airway and prevent aspiration. Keep patient quiet and maintain normal body temperature. Obtain medical attention. /Poisons A and B/|/SRP:/ Basic treatment: Establish a patent airway (oropharyngeal or nasopharyngeal airway, if needed). Suction if necessary. Watch for signs of respiratory insufficiency and assist ventilations if needed. Administer oxygen by nonrebreather mask at 10 to 15 L/min. Monitor for pulmonary edema and treat if necessary ... . Monitor for shock and treat if necessary ... . Anticipate seizures and treat if necessary ... . For eye contamination, flush eyes immediately with water. Irrigate each eye continuously with 0.9% saline (NS) during transport ... . Do not use emetics. For ingestion, rinse mouth and administer 5 mL/kg up to 200 mL of water for dilution if the patient can swallow, has a strong gag reflex, and does not drool ... . Cover skin burns with dry sterile dressings after decontamination ... . /Poisons A and B/|/SRP:/ Advanced treatment: Consider orotracheal or nasotracheal intubation for airway control in the patient who is unconscious, has severe pulmonary edema, or is in severe respiratory distress. Positive-pressure ventilation techniques with a bag valve mask device may be beneficial. Consider drug therapy for pulmonary edema ... . Consider administering a beta agonist such as albuterol for severe bronchospasm ... . Monitor cardiac rhythm and treat arrhythmias as necessary ... . Start IV administration of D5W TKO /SRP: "To keep open", minimal flow rate/. Use 0.9% saline (NS) or lactated Ringer's (LR) if signs of hypovolemia are present. For hypotension with signs of hypovolemia, administer fluid cautiously. Watch for signs of fluid overload ... . Treat seizures with diazepam or lorazepam ... . Use proparacaine hydrochloride to assist eye irrigation ... . /Poisons A and B/|Emergency and supportive measures. 1. Maintain an open airway and assist ventilation if necessary. 2. Treat coma, seizures, hypotension, anaphylaxis, and hemolysis if they occur. 3. replace fluid losses resulting from gastroenteritis with IV crystalloids. 4. Maintain steady urine flow with fluids to alleviate crystalluria from overdoses of sulfonamides, ampicillin, or amoxicillin. /Antibacterial agents/|For more Antidote and Emergency Treatment (Complete) data for AVILAMYCIN (6 total), please visit the HSDB record page.

/SIGNS AND SYMPTOMS/ Avilamycin may be irritating to the eyes and may cause allergic reactions in those hypersensitive to avilamycin. Avoid inhalation, oral exposure, and direct contact with skin or eyes.

avilamycin

Oral (feed): Avilamycin 90.7 g per lb (200 g per kg) (Kavault)

Avilamycin A is the main component; avilamycins B through N are also known and are derivatives of A differing at the C-45 linkage and/or the C-56 ketone adduct.

A gas chromatographic (GC) procedure is presented for the determination of residues of avilamycin and all its metabolites/conjugates which can be converted to the common moiety dichloroisoeverninic acid (DIA). The method involves alkaline hydrolysis to DIA, cleanup by partitioning with chloroform, acidification of the aqueous phase, and partitioning of DIA into methylene chloride. After methylation of DIA, the product, 3,5-dichloro-4,6-dimethoxy-2-methylbenzoic acid methyl ester, is cleaned up on a silica gel column prior to the final determination by electron capture GC. The method is sensitive to 0.1 mg/kg avilamycin equivalent. Overall average recoveries were 85.4%, with a standard deviation of 9.1% for n = 20. Analyses of feces, urine, tissues, and fat of pigs treated with avilamycin demonstrated that 93% of the administered substance is excreted in feces and urine, within 72 hr after treatment, and that no residues (less than 0.01 mg/kg) can be found in the tissues and fat of the animals at any time between 0 and 7 days after treatment with medicated feed.

Animal Drugs -> FDA Approved Animal Drug Products (Green Book) -> Active Ingredients|Veterinary Drug -> ANTIMICROBIAL_AGENT; -> JECFA Functional Classes

Veterinary Drug -> ANTIMICROBIAL_AGENT;